Monopar Therapeutics (MNPR) Return on Equity [ROE] (2018 - 2026)
Monopar Therapeutics (MNPR) reported Return on Equity [ROE] of -10.32% for Q2 2026, up 5.31 percentage points from -15.63% a year earlier.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Return on Equity [ROE] (2018 - 2026) Analysis & Trends
For FY2025, Monopar Therapeutics posted Return on Equity [ROE] of -14.22%, up 37.19 percentage points from FY2024.
- Return on Equity [ROE] has a five-year change of +31.74 percentage points (FY2020 to FY2025).
- By year, Return on Equity [ROE] came in at -51.42% in FY2024 (+55.77 pp), -107.19% in FY2023 (-34.59 pp), -72.60% in FY2022 (-19.89 pp) and -52.71% in FY2021 (-6.74 pp).
- Five-year quarterly Return on Equity [ROE] spans a low of -142.94% in Q4 2023 and a high of -10.31% in Q3 2025.
- The high point for year-over-year Return on Equity [ROE] in five years was Q3 2025 (a gain of 111.89 percentage points); the low point was Q3 2023 (a drop of 58.21 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Monopar Therapeutics | 666.05 Mn | 384.28 Mn | - | -10.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.32% |
| Sep 30, 2025 | -10.31% |
| Jun 30, 2025 | -15.63% |
| Mar 31, 2025 | -13.73% |
| Sep 30, 2024 | -122.21% |
| Jun 30, 2024 | -106.46% |
| Mar 31, 2024 | -119.94% |
| Dec 31, 2023 | -142.94% |
| Sep 30, 2023 | -134.49% |
| Jun 30, 2023 | -121.20% |
| Mar 31, 2023 | -111.43% |
| Dec 31, 2022 | -93.25% |
| Sep 30, 2022 | -76.29% |
| Jun 30, 2022 | -65.82% |
| Mar 31, 2022 | -53.97% |
| Dec 31, 2021 | -45.39% |
| Sep 30, 2021 | -39.02% |
| Jun 30, 2021 | -32.59% |
| Mar 31, 2021 | -35.63% |
| Dec 31, 2020 | -39.23% |
API Access
Monopar Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MNPR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "MNPR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MNPR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();